{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-006001","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.260065+00:00","generated_at":"2026-05-17T13:55:18.397881+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Xenetic Biosciences Q2 2025 net loss $0.7M; cash $4.8M; expands Scripps partnership","bullets":["Net loss ~$0.7M for Q2 2025; no revenue reported.","R&D expenses fell 29.7% to ~$0.7M; G&A down 41.8% to ~$0.7M vs Q2 2024.","Cash at quarter-end ~$4.8M to fund operations.","Expanded collaboration with Scripps Research Institute for DNase I plus CAR T-cell studies.","Partner PeriNess commenced patient dosing in pancreatic cancer study; exploratory CAR T study in large B cell lymphoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-006001","json":"https://secwatch.observer/filing/0001683168-25-006001.json","markdown":"https://secwatch.observer/filing/0001683168-25-006001.md","text":"https://secwatch.observer/filing/0001683168-25-006001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316825006001/0001683168-25-006001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316825006001/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:55:18.397881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}